Landscape Capital Management L.L.C. acquired a new position in shares of Medtronic PLC (NYSE:MDT – Free Report) during the 3rd quarter, Holdings Channel.com reports. The firm acquired 10,898 shares of the medical technology company’s stock, valued at approximately $940,000.
A number of other hedge funds have also recently added to or reduced their stakes in the business. First Eagle Investment Management LLC boosted its stake in Medtronic by 37.2% in the second quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock valued at $1,078,321,000 after acquiring an additional 3,739,288 shares during the period. Cullen Capital Management LLC acquired a new position in Medtronic during the 2nd quarter valued at approximately $202,764,000. State Street Corp boosted its position in Medtronic by 2.7% during the 2nd quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock valued at $5,005,320,000 after purchasing an additional 1,658,301 shares during the period. Amundi grew its stake in Medtronic by 36.3% during the 1st quarter. Amundi now owns 6,070,236 shares of the medical technology company’s stock worth $525,986,000 after buying an additional 1,616,739 shares during the last quarter. Finally, Bank of America Corp DE increased its position in Medtronic by 5.4% in the first quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock worth $2,254,200,000 after buying an additional 1,343,220 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.
Medtronic Stock Down 0.1%
Shares of MDT stock opened at $100.57 on Friday. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The stock has a market cap of $128.64 billion, a PE ratio of 24.77, a price-to-earnings-growth ratio of 2.36 and a beta of 0.56. The business’s fifty day moving average is $94.44 and its 200-day moving average is $88.47. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07.
Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The business had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. During the same quarter in the prior year, the firm posted $1.26 earnings per share. The company’s revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities analysts expect that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on MDT shares. Robert W. Baird raised their target price on Medtronic from $91.00 to $100.00 and gave the company a “neutral” rating in a research note on Wednesday, September 2nd. Stifel Nicolaus upped their price target on shares of Medtronic from $80.00 to $95.00 and gave the stock a “hold” rating in a research report on Wednesday, September 2nd. Piper Sandler raised shares of Medtronic from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $85.00 to $120.00 in a report on Tuesday. Wells Fargo & Company lifted their price objective on shares of Medtronic from $102.00 to $104.00 and gave the company an “overweight” rating in a research report on Wednesday, September 2nd. Finally, Deutsche Bank reissued a “hold” rating and set a $92.00 target price on shares of Medtronic in a research note on Thursday, September 3rd. Eighteen research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and a consensus target price of $104.17.
Check Out Our Latest Stock Analysis on MDT
Key Medtronic News
Here’s some of the latest news about MDT:
- Positive Sentiment: BTIG Research raised its price target on Medtronic to $109 from $99 and reiterated a Buy rating, signaling confidence in further upside. BTIG Research rating and price target
- Neutral Sentiment: A preview of Medtronic’s fiscal second-quarter results focused on expected metrics but did not report actual results, leaving investors awaiting the earnings update. Medtronic Q2 earnings preview
- Negative Sentiment: The outlook discussion also flags margin and currency headwinds, which could limit the benefit of growth in Hugo, international markets and Neuroscience. Medtronic hold analysis
Insider Activity at Medtronic
In other Medtronic news, EVP Harry Kiil sold 1,483 shares of the business’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the sale, the executive vice president owned 42,186 shares in the company, valued at approximately $3,950,718.90. The trade was a 3.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Geoffrey Martha sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the sale, the chief executive officer owned 277,866 shares in the company, valued at $26,397,270. This represents a 15.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 61,903 shares of company stock valued at $5,889,203 over the last ninety days. Insiders own 0.27% of the company’s stock.
Medtronic Profile
Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.
See Also
- Five stocks we like better than Medtronic
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
